ISTA and RIGL pipeline updates. CRTX NDA filing + NEOL GEVA NAVB news

Jan 05, 2012 No Comments by

Cornerstone Therapeutics (NASDAQ: CRTX) yesterday announced that it had acquired Cardiokine Inc. Cardiokine filed a New Drug Application (NDA) for its lead compound, lixivaptan for treatment of hyponatremia on Dec. 29, 2011.

INSYS Therapeutics (pinksheets:NEOL) today announced it had received FDA approval of its cancer pain medication, SUBSYS fentanyl sublingual spray.

ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA) gave a pipeline update after hours yesterday. There were some subtle changes in the wording of their update compared with previous guidance.

  • NDA for Prolensa, a once-daily formulation of BROMDAY for postoperative inflammation and reduction of ocular pain pos-cataract extraction, is due to be filed 1H 2012. It mentioned in November 2011 that it hoped to file the NDA during 1Q 2012.
  • Phase 2 preliminary data of its Beposone Mountain Cedar Pollen results for seasonal allergic rhinitis are due 1H 2012.
  • Phase 3 initiation of T-PRED for uveitis and allergic conjunctivitis is expected during 2H 2012.

Rigel Pharmaceuticals, Inc. (RIGL: Nasdaq) today gave an update noting that it expects to initiate a Phase 2 trial of R343, an inhaled SYK inhibitor, for patients with allergic asthma in mid-2012. In addition, its collaborator on fostamatinib, AstraZeneca (AZ), has indicated that the Phase 3 studies in rheumatoid arthritis are continuing as planned with the first study completing enrolment during 4Q 2011.   AZ expects to file a New Drug Application (NDA) for fostamatinib in 2013.

Synageva BioPharma Corp. (NASDAQ:GEVA), announced a $60m public offering of 3,108,057 shares at $25.18 per share.

Neoprobe Corporation (NYSE Amex: NEOP) changed its company name and ticker today. It is now called Navidea Biopharmaceuticals, Inc. and trades under the ticker, NAVB.

Daily News

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.
No Responses to “ISTA and RIGL pipeline updates. CRTX NDA filing + NEOL GEVA NAVB news”

Leave a Reply